Human bladder cancer invasion model using rat bladder in vitro and its use to test mechanisms and therapeutic inhibitors of invasion.
As well as being a passive support, the extracellular matrix also regulates key biological processes such as invasion, differentiation and angiogenesis. We have therefore developed an in vitro model of bladder cancer invasion using de-epithelialized rat bladder to allow for tumour cell-extracellular matrix interactions. Onto this we have seeded a panel of human bladder cancer cell lines (RT4, RT112, 253J and EJ28 (T24)) representing progression from well to poorly differentiated phenotypes and used as models of superficial to invasive bladder cancer. The better differentiated cell lines RT4 and RT112 reproducibly grew as stratified epithelium, whereas poorly differentiated EJ28 cells invaded across a broad front. Invasion was not simply related to proliferation rate, measured either as doubling time on plastic (non-invasive 253J and invasive EJ28 having the same doubling time) or by Ki-67 proliferation index within the model. We used the model to test the ability of 4 compounds that interfere with tumour cell-extracellular matrix interactions (suramin, N-acetylcysteine and the urokinase plasminogen activator pathway antagonists A5 compound and monoclonal antibody Mab 3936) to inhibit invasion. At non-toxic concentrations, all significantly inhibited invasion (P< 0.05), although to varying degrees, suramin and A5 almost completely and N-acetylcysteine the least. In conclusion, this model shows the urokinase system is important for bladder invasion and can be used to investigate other mechanisms of bladder cancer invasion and also for the testing of intravesical drugs.
Fujiyama
C
C
Molecular Oncology Unit, ICRF, Institute of Molecular Medicine, John Radcliffe Hospital, Oxford, OX3 9DS, UK.
Jones
A
A
Fuggle
S
S
Bicknell
R
R
Cranston
D
D
Harris
A L
AL
D000111:Acetylcysteine / Q000494:pharmacology; D000283:Administration, Intravesical; D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology; D002295:Carcinoma, Transitional Cell / Q000188:drug therapy / Q000473:pathology*; D002454:Cell Differentiation; D002455:Cell Division; D004195:Disease Models, Animal; D004354:Drug Screening Assays, Antitumor; D004848:Epithelium / Q000473:pathology; D006801:Humans; D009361:Neoplasm Invasiveness / Q000503:physiopathology*; D010641:Phenotype; D051381:Rats; D017207:Rats, Sprague-Dawley; D013498:Suramin / Q000494:pharmacology; D014407:Tumor Cells, Cultured; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy / Q000473:pathology*; D014568:Urokinase-Type Plasminogen Activator / Q000037:antagonists & inhibitors / Q000378:metabolism*
D000970:Antineoplastic Agents; D013498:Suramin; D014568:Urokinase-Type Plasminogen Activator; D000111:Acetylcysteine